522 related articles for article (PubMed ID: 16875720)
1. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis.
Bristow RE; Chi DS
Gynecol Oncol; 2006 Dec; 103(3):1070-6. PubMed ID: 16875720
[TBL] [Abstract][Full Text] [Related]
2. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis.
Bristow RE; Puri I; Chi DS
Gynecol Oncol; 2009 Jan; 112(1):265-74. PubMed ID: 18937969
[TBL] [Abstract][Full Text] [Related]
3. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer.
Gadducci A; Iacconi P; Cosio S; Fanucchi A; Cristofani R; Riccardo Genazzani A
Gynecol Oncol; 2000 Dec; 79(3):344-9. PubMed ID: 11104603
[TBL] [Abstract][Full Text] [Related]
4. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease.
Ho CM; Huang YJ; Chen TC; Huang SH; Liu FS; Chang Chien CC; Yu MH; Mao TL; Wang TY; Hsieh CY
Gynecol Oncol; 2004 Jul; 94(1):197-203. PubMed ID: 15262142
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease.
Hou JY; Kelly MG; Yu H; McAlpine JN; Azodi M; Rutherford TJ; Schwartz PE
Gynecol Oncol; 2007 Apr; 105(1):211-7. PubMed ID: 17239941
[TBL] [Abstract][Full Text] [Related]
6. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study.
Eisenkop SM; Friedman RL; Wang HJ
Gynecol Oncol; 1998 May; 69(2):103-8. PubMed ID: 9600815
[TBL] [Abstract][Full Text] [Related]
7. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
[TBL] [Abstract][Full Text] [Related]
8. Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies.
Kang S; Nam BH
Ann Surg Oncol; 2009 Aug; 16(8):2315-20. PubMed ID: 19517192
[TBL] [Abstract][Full Text] [Related]
9. Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer?
Aletti GD; Long HJ; Podratz KC; Cliby WA
Gynecol Oncol; 2007 Jan; 104(1):212-6. PubMed ID: 17023033
[TBL] [Abstract][Full Text] [Related]
10. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer.
Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Aghajanian C; Barakat RR; Chi DS
Gynecol Oncol; 2008 Feb; 108(2):276-81. PubMed ID: 18063020
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer.
Vergote IB; De Wever I; Decloedt J; Tjalma W; Van Gramberen M; van Dam P
Semin Oncol; 2000 Jun; 27(3 Suppl 7):31-6. PubMed ID: 10952124
[TBL] [Abstract][Full Text] [Related]
12. Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study.
Gadducci A; Sartori E; Landoni F; Zola P; Maggino T; Maggioni A; Cosio S; Frassi E; LaPresa MT; Fuso L; Cristofani R
J Clin Oncol; 2005 Feb; 23(4):751-8. PubMed ID: 15613698
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy for advanced ovarian cancer.
Schwartz PE; Chambers JT; Makuch R
Gynecol Oncol; 1994 Apr; 53(1):33-7. PubMed ID: 8175019
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study.
Ansquer Y; Leblanc E; Clough K; Morice P; Dauplat J; Mathevet P; Lhommé C; Scherer C; Tigaud JD; Benchaib M; Fourme E; Castaigne D; Querleu D; Dargent D
Cancer; 2001 Jun; 91(12):2329-34. PubMed ID: 11413522
[TBL] [Abstract][Full Text] [Related]
15. Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer.
Gadducci A; Iacconi P; Fanucchi A; Cosio S; Teti G; Genazzani AR
Anticancer Res; 2000; 20(3B):1959-64. PubMed ID: 10928134
[TBL] [Abstract][Full Text] [Related]
16. The results of treatment of epithelial ovarian cancer after centralisation of primary surgery. Results from North Jutland, Denmark.
Soegaard Andersen E; Knudsen A; Svarrer T; Lund B; Nielsen K; Grove A; Tetsche M
Gynecol Oncol; 2005 Dec; 99(3):552-6. PubMed ID: 16150480
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas.
Matsuo K; Eno ML; Im DD; Rosenshein NB
Arch Gynecol Obstet; 2010 Feb; 281(2):325-8. PubMed ID: 19455347
[TBL] [Abstract][Full Text] [Related]
18. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Pectasides D; Fountzilas G; Aravantinos G; Kalofonos HP; Efstathiou E; Salamalekis E; Farmakis D; Skarlos D; Briasoulis E; Economopoulos T; Dimopoulos MA
Gynecol Oncol; 2005 May; 97(2):436-41. PubMed ID: 15863142
[TBL] [Abstract][Full Text] [Related]
19. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
[TBL] [Abstract][Full Text] [Related]
20. Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction.
Sood AK; Sorosky JI; Gelder MS; Buller RE; Anderson B; Wilkinson EJ; Benda JA; Morgan LS
Cancer; 1998 May; 82(9):1731-7. PubMed ID: 9576296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
